Early retired from civil service 8 April 2022
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$THER - we should hear something from the company this week regarding comments and responses to SEC. Merger and uplisting is on us, are you ready?
LCJR
Damn, did you really need to sell those 14s for a whopping $900 ?
LCJR
Anything driving this? Would be nice to see our shares increase in value finally.
LCJR
Wow, somebody is moving on to the next shiny object. We’ll bounce back soon.
LCJR
Would be nice, but we’ve been saying that for quite some time now. If they’d lay out a projected timeline or business roadmap it would allow more realistic expectations.
LCJR
Lots of upcoming catalysts. Most likely get some real good news the week, but the real drive is the heavy accumulation recently.
LCJR
I posted earlier that I emailed them requesting a meeting and never heard from them. But right after I emailed them they put out that last PR. If they would respond I would gladly drive the 1 1/2 hour drive to meet with them.
LCJR
It’s on its way.
LCJR
Buy me out, please. They can have my shares at $5
LCJR
That’s correct, but the uplifting to Nasdaq is also part of the merger. If they have everything approved by SEC, upon completion of merger, this could open up on Nasdaq with a PPS over $2
LCJR
If only a fraction had brokerage accounts and bought shares.
LCJR
Hard pass? They will be listed on Nasdaq after that, which is also in the filings. At this price, you could buy a few mill and have enough after the RS to make awesome money. But to each his/her own.
LCJR
So what’s the price prediction thru 2024?
LCJR
This is about to draw in a lot of attention. Especially when folks find out they’re merging with a Nasdaq company. Next week might be the end of anything under 005 opportunities.
LCJR
Just put him on ignore like most have done. Not worth reading his dribble.
LCJR
I’m adding more tomorrow. That news woke me up.
LCJR
I’m super excited for that! Unless I’m reading level2 wrong, it’s extremely thin once we get past 0086.
LCJR
Getting past .0080 and holding it is proving difficult right now. I already added again this morning so I’m eager as well for this to get going.
LCJR
$THER - those sell orders showing on the ticker tape are actually buys. I know because I bought them this morning at 0014 and 0015.
LCJR
Still holding strong. Picked up a few more today too.
LCJR
News out!
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (Nasdaq: BACK), announce that the companies have responded to the SEC’s first round of comments on the jointly filed form S-4. A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition. The Companies previously filed the S-4 on September 29th and received comments from the SEC in late October.
Theralink’s Chief Executive Officer, Faith Zaslavsky previously stated “The filing of the Form S-4 is a major milestone, as it signifies Theralink and IMAC have reached a definitive agreement and that the transaction is moving forward. The result of the Merger will be a well-positioned proteomics pure play squarely focused on the next generation of cancer care and protein analysis, an opportunity that all stakeholders in our companies are highly excited about. I am unaware of any other proteomics company with a robust patent estate, certified and accredited laboratory, and reimbursement agreements in place with major payors like Medicare that parallels what our new combined company possesses along with the leadership to execute and build value.”
The companies expect to hear back from the Securities and Exchange Commission within the next 10 business days.
LCJR
$DLOC - I just found this so I’ll be in tomorrow. Not much from the company on X but I’m sure eventually they’ll start an effective marketing campaign.
LCJR
Monday we need to get over .70 and hold it. Tues-Wes we could see .80.
LCJR
That’s how the filing reads.
LCJR
I reached out to the company to set up an appointment to meet and talk but never got a response back from them. Curious after my email they immediately released that last PR.
I can understand if they’re in a quiet period, but it is allowed to let everyone know they’re in a quiet period instead of just ignoring folks. I didn’t care for that.
LCJR
Give it up dude. Maybe the owner is retiring or maybe a hundred other valid reasons. If you don’t like this, move on.
LCJR
Ah, gotcha. Yep, I think that’s what’s going to happen. First the share structure changes and then the merger with uplisting request if it’s not already in the works. It will hit when everyone’s sleeping on this, but end of 4th QTR is end of December so time is running out to gather shares.
LCJR
You read the filings, right? Share structure is about to be reduced.
LCJR
I have Twitter and FB just because companies are now allowed to disseminate information thru these platforms. I also use them to learn what others are doing related to my interests. You don’t have to post anything, just read.
LCJR
My TD Ameritrade moved to Schwab a few months ago and I lost level2. Now I downloaded the Think or Swim app from the Schwab site, logged in using my Schwab info and now I have level2 again. If you have a margin account you can trade using that app, if not you still get free level2.
LCJR
$THER. News out:
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute (Inova) is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova’s Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients.
The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova’s molecular tumor board’s operational workflow. Over the past year, Inova has undertaken a feasibility study to develop and implement the procedures and infrastructure necessary for proteomic analysis within the context of the Inova Schar Molecular Tumor Board. The Theralink assay provides a direct means of determining the actionability of genomic derangements identified, as well as directly measuring the activation/elevation of protein drug targets otherwise missed by genomic analysis alone. Thus, the incorporation of key phosphoprotein and protein data generated by Theralink’s RPPA technology into the Inova MTB could synergize with current genomics analysis to produce more accurate treatment selection and patient-tailored therapy regimes.
Interim results of this pan-tumor study were presented at the 2023 ASCO Conference in Chicago. Specifically, the analysis examined the feasibility of incorporating laser capture microdissection (LCM) enrichment of tumor specimens and reverse phase protein array (RPPA) analysis with next generation sequencing (NGS) into a molecular tumor board for improving selection of targeted cancer therapy. Integrated review of the RPPA and NGS data by the MTB supported a clinical recommendation change for over half of the patients overall. Further, the proteomics data from the Theralink assay provided additional treatment considerations for 59% of the patients, the outcomes for whom continue to be monitored. Moreover, the collaboration with Inova and their MTB resulted in a recent finding1 wherein the Theralink proteomics data revealed a specific mechanism of resistance and likely lack of benefit to a targeted therapy being considered by the MTB for a patient with a rare form of inflammatory myofibroblastic cancer.
Lastly, Inova and Theralink presented the results of another important study at ASCO 2023 that focused on Theralink’s unique ability to quantitatively measure HER2 abundance and activation and found that nearly 50% of pancreatic tumor actually express moderate amounts of HER2 protein, which could be missed by existing commercial HER2 assays. While HER2 expression is not routinely evaluated in clinical practice for pancreatic cancer these results may have clinical implications, especially as new classes of HER2 antibody drug conjugates are considered for patients with HER2 non amplified tumors across organ sites.
“Theralink is extremely encouraged by the work done to date at Inova Schar Cancer Institute- the interim results and clinical intelligence speak for themselves. We look forward to completing this study with Inova for our mutual goal of improving outcomes for all cancer patients”, said Faith Zaslavsky, President and Chief Executive Officer of Theralink.
Dr. Timothy Cannon, who is the Sheridan Director of the Inova Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova said, “We have tested over 100 patients with Theralink’s RPPA technology as part of this study. We are hopeful final study analysis and results will continue to underscore the importance of real-time clinical integration of functional protein drug target activation data provided by the Theralink assay with NGS in the Inova MTB for cancer patients.”
Theralink and Inova will update findings and results post study completion. Published results are anticipated in early 2024.
Moving along at a rapid pace. They want this done!
LCJR
Do you go visit each company you invest or play? I think not. We rely on research.
Eye rolls.
LCJR
Easy hold for those that can read. They’ve delivered everything as promised and now the super 8K comes within a few days, like you stated.
Folks, don’t let these guys talk you out of your shares. Do your own DD, read the filings, and wait.
LCJR
You’ll be waiting in vain. Don’t see it dropping like that.
LCJR
That can happen as investors decide to hold or take profits. It’s normal. Volatility is normal during these big events and major changes. All we have to do is hold thru this until completion or move on to something else. It does no good to spread fear unnecessarily.
LCJR
What’s not adding up now? You’re becoming depressing with your constant worrying. If you have any doubt, just sell and get into another play. But you should know any ticker going thru any type of merger or change in business plan is going to be volatile until things are completed. The only change I’m seeing is shares changing out of the hands of those that expected to be rich already and have no patience to see this crossing the finish line. We're right there at the finish line and everything that was supposed to happen has indeed happened.
LCJR
Oh, that’s what you meant. I said I plan on it on my next free day. Right now I’m working almost every day and when I’m off I have family obligations. I’ll make my way to their office when I can.
LCJR
I’m loaded and holding. We’re supposed to be getting some news before end of quarter. I can sit and wait on this one.
LCJR